Project Grant F30CA287792
Award Date
8/23/24
Completion Date
2/28/28
Dollars Obligated
$253K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $600,499 Project Grant under the Cancer Biology Research (CFDA 93.396) federal grant program to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The award period runs from April 1, 2025 to March 31, 2030. The project aims to investigate the role of the oral anaerobe Fusobacterium nucleatum (FN) and its adhesin FadA protein in colorectal cancer (CRC) oncogenesis. Specifically, the researchers...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $193,144 to The Trustees of Columbia University in the City of New York to support a multidisciplinary postdoctoral training program focused on gastrointestinal (GI) cancers. The 5-year program, running from September 1, 2024 to August 31, 2029, aims to train the next generation of GI cancer researchers across basic science, translational, clinical, epidemiological, and...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $281,606 to New York University School of Medicine to conduct research aimed at harnessing gut-derived bacteria to drive anti-tumor immunity in lung cancer. The 5-year project, led by Dr. Rabi Upadhyay, an Assistant Professor at NYU, will investigate the mechanism by which certain gut commensals can trigger systemic anti-tumor immune responses, even in the absence...
The National Cancer Institute (NCI) awarded a $400,890 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The 3-year grant, effective March 1, 2025, aims to profile patient-specific tumor-microbiome interactions and conduct quantitative molecular analyses to elucidate microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient and microsatellite-stable...
This $353,843 Project Grant awarded by the National Science Foundation (NSF) under the Engineering program (CFDA 47.041) will support the development of programmable and dynamically-responsive bacterial therapeutics for cancer immunotherapy. The project aims to create a novel biosensing system in E. coli bacteria that can recognize extracellular cancer antigens and respond with therapeutic payloads. In parallel, the researchers will engineer bacteria with improved tumor colonization capabilities...
This $626,893 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Texas MD Anderson Cancer Center will fund research to study the role of bacterial-colonized microniches within tumors and their impact on intratumoral heterogeneity. The research aims to: 1) functionally map the cellular and metabolic features of these bacterial microniches within patient tumor tissues, 2) delineate the human cell types harboring intracellular...
The U.S. National Cancer Institute (NCI) awarded a $626,534 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Medical University of South Carolina (MUSC) to support a 5-year research project titled "Dissecting the Mechanism for Transient ER Stress-Induced Anti-Tumor T Cell Response." The project aims to investigate how transient endoplasmic reticulum (ER) stress can improve the function and anti-tumor efficacy of T cells, particularly through modulating mitochondrial...
The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.395 "Cancer Treatment Research" to the University of Texas Health Science Center at Houston. The $406,611 grant, awarded on April 1, 2025, will fund research to investigate the role and therapeutic targeting of the GPR56 protein in colorectal cancer. The key objectives are to: Characterize the function and signaling mechanisms of GPR56 in colorectal cancer stem cells and metastasis using patient-derived...
The National Cancer Institute (NCI) has awarded a $435,773 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Maryland, Baltimore (UMB) to develop an engineered prodrug capable of selectively delivering potent cytotoxins to malignant tumor cells. The goal is to leverage hyperactive membrane-anchored serine proteases (MASPs) on the surface of tumor cells to activate the prodrug and selectively kill cancer cells, particularly in ovarian, lung, and colon cancers. The...
The Project Grant award of $218,886.00 from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports the development of a novel technology for targeted protein degradation in cancer cells. The project, led by The Trustees of Columbia University in the City of New York, aims to leverage light-activated, target-localized protein cleavage reactions to degrade key cancer proteins, such as the immune checkpoint receptor PD-1 and the oncogenic phosphatase SHP2, with high spatial...